3Schiller JH, Harrington D,Belani CP,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med,2002,346(1) : 92-98.
4Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation[J]. Eur J Cancer,2001,37(13) : 1590-1598.
5Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyroaine kinase,in symtomatic patients with non-small cell lung cancer: a randomized trial[J]. JAMA,2003,290(16);2149 2158.
6Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non small cell lung cancer[J]. J Clin Oncol,2003,21(12) : 2237-2246.
7Perez-Soler R,Chaehoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non -small-cell lung cancer[J]. J Clin Oncol, 2004,22 (16) : 3238-3247.
8Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-celt lung cancer[J]. N Engl J Med,2005,353(2) : 123-132.
9Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management [J]. J Am Coil Cardiol,2009,53(24) :2231-2247.
